antibody

RASSF1A

MBS603739

0.05 mL

340 USD

monoclonal

mouse

nonconjugated

5G1

western blot, ELISA, immunocytochemistry, enzyme immunoassay

Antibody

RASSF1A

RASSF1A

Anti -RASSF1A

ras association domain-containing protein 1 isoform B; Ras association domain-containing protein 1; ras association domain-containing protein 1; WUGSC:H_LUCA12.5; tumor suppressor protein RDA32; cardiac-specific ras association domain family 1 protein; pancreas-specific ras association domain family 1 protein; Ras association (RalGDS/AF-6) domain family member 1

RASSF1; RASSF1; 123F2; RDA32; NORE2A; RASSF1A; REH3P21; RDA32

RASF1_HUMAN

Monoclonal

IgG1,k

5G1

Mouse

Human

Recognizes human RASSF1A.

Affinity Purified. Purified by Protein G affinity chromatography.

Supplied as a liquid in PBS, pH 7.4.

May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

ELISA (EL/EIA), Western Blot (WB), Immunofluorescence (IF)

Suitable for use in ELISA, Western Blot and Immunofluorescence (IF-IC). Dilution: Western Blot:1:500-1:2000

Immunogen: Recombinant corresponding to aa1-340 from human RASSF1A purified from E. coli.

Hybridoma: Mouse SP2/O myeloma cells with spleen cells from BALB/c mice immunized with a recombinant human RASSF1A protein.

Antibodies; Abs to Apoptosis

The tumor suppressor gene RASSF1A (3p21.3), human Ras association domain family 1A, is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, small intestine, colon, and peripheral blood leukocytes. RASSF1A expression is inhibited by hypermethylation of the CpG island including the promoter and early transcribed regions of the human RASSF1A gene. Hypermethylated RASSF1A promoter is observed in primary tumors. Furthermore, RASSF1A is related with cell cycle regulation, apoptosis and microtubule stability.

332701155

NP_001193886.1

NM_001206957.1

Q9NS23

39,219 Da

Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Hippo Signaling Pathway (749777); Hippo Signaling Pathway (750388); MicroRNAs In Cancer Pathway (852705); MicroRNAs In Cancer Pathway (852928); Non-small Cell Lung Cancer Pathway (83119); Non-small Cell Lung Cancer Pathway (531); Pathways In Cancer (83105); P53 Pathway (138067)

This gene encodes a protein similar to the RAS effector proteins. Loss or altered expression of this gene has been associated with the pathogenesis of a variety of cancers, which suggests the tumor suppressor function of this gene. The inactivation of this gene was found to be correlated with the hypermethylation of its CpG-island promoter region. The encoded protein was found to interact with DNA repair protein XPA. The protein was also shown to inhibit the accumulation of cyclin D1, and thus induce cell cycle arrest. Several alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. [provided by RefSeq, May 2011]

RASSF1: Potential tumor suppressor. Required for death receptor- dependent apoptosis. Mediates activation of STK3/MST2 and STK4/MST1 during Fas-induced apoptosis by preventing their dephosphorylation. When associated with MOAP1, promotes BAX conformational change and translocation to mitochondrial membranes in response to TNF and TNFSF10 stimulation. Isoform A interacts with CDC20, an activator of the anaphase-promoting complex, APC, resulting in the inhibition of APC activity and mitotic progression. Inhibits proliferation by negatively regulating cell cycle progression at the level of G1/S-phase transition by regulating accumulation of cyclin D1 protein. Isoform C has been shown not to perform these roles, no function has been identified for this isoform. Isoform A disrupts interactions among MDM2, DAXX and USP7, thus contributing to the efficient activation of TP53 by promoting MDM2 self-ubiquitination in cell-cycle checkpoint control in response to DNA damage. Interacts with MAP1S and XPA. Binds to the N-terminal of CDC20 during prometaphase. Binds to STK3/MST2 and STK4/MST1. Isoform A interacts with MOAP1 and E4F1. Recruited to the TNFRSF1A and TNFRSF10A complexes in response to their respective cognate ligand, after internalization. Can self-associate. Isoform A interacts with RSSF5 and probably associates with HRAS1 via a RSSF1 isoform A-RSSF5 heterodimer. Part of a complex with MDM2, DAXX, RASSF1 and USP7. Isoform A interacts (via C-terminus) with DAXX (via N-terminus); the interaction is independent of MDM2 and TP53. Isoform C or isoform H interacts (via N-terminus) with DAXX. Isoform A interacts (via N-terminus) with MDM2 (via C-terminus); the interaction is independent of TP53. Isoform A and isoform C are ubiquitously expressed in all tissues tested, however isoform A is absent in many corresponding cancer cell lines. Isoform B is mainly expressed in hematopoietic cells. 8 isoforms of the human protein are produced by alternative promoter. Protein type: Tumor suppressor. Chromosomal Location of Human Ortholog: 3p21.3. Cellular Component: microtubule cytoskeleton; spindle pole; microtubule; cytoplasm; plasma membrane; microtubule organizing center; nucleus. Molecular Function: identical protein binding; protein binding; zinc ion binding; protein N-terminus binding. Biological Process: protein stabilization; positive regulation of protein ubiquitination; Ras protein signal transduction; cell cycle arrest; response to DNA damage stimulus. Disease: Lung Cancer

0.05 mL

340 USD

0.1 mL

425